Editorial Expression of Concern: Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures

Jun Iwamoto¹ · Mitsuyoshi Uzawa²

Published online: 18 June 2021

© International League of Associations for Rheumatology (ILAR) 2021

Editorial Expression of Concern: Clin Rheumatol (2016) 35:205–212

<https://doi.org/10.1007/s10067-014-2812-y>

Following receipt of a concern from a reader about this article [1], the Editor-in-Chief is issuing an editorial expression of concern to highlight the large overlap between this article and another article by the same author group [2]. Whilst there is a high percentage of overlap, the Editor-in-Chief considers this article to be sufficiently novel to warrant its inclusion in the scientific record. Jun Iwamoto has not responded to correspondence from the Editor-in-Chief or publisher. The Editor-in-Chief and the publisher were not able to obtain a current email addresses for Mitsuyoshi Uzawa.

References

1. Iwamoto J, Uzawa M (2016) Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. *Clinical Rheumatology* 35(1): 205–212
2. Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H (2010) Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures. *Therapeutics and Clinical Risk Management* 6:593–600

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s10067-014-2812-y>

✉ Jun Iwamoto
jiwamoto@a8.keio.jp

¹ Institute for Integrated Sports Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

² Department of Orthopaedic Surgery, Keiyu Orthopaedic Hospital, Gunma, Japan